Portal de Periódicos da CAPES

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

2014; Elsevier BV; Volume: 124; Issue: 6 Linguagem: Inglês

10.1182/blood-2014-03-563577

1528-0020

Jan Beyer‐Westendorf, Kati Förster, Sven Pannach, Franziska Ebertz, Vera Gelbricht, Christoph Thieme, Franziska Michalski, Christina Köhler, Sebastian Werth, Kurtuluş Şahin, Luise Tittl, Ulrike Hänsel, Norbert Weiss,

Cardiac Arrhythmias and Treatments

Key Points In a real-world setting, annualized bleeding rates of major rivaroxaban bleeding are lower than those reported for vitamin K antagonists. Treatment of major rivaroxaban bleeding is simple and rarely requires pro-coagulants; outcome at 90 days is better than that reported for vitamin K antagonists.